Xie, Ting Lim, Sang Min Westover, Kenneth D. Dodge, Michael E. Ercan, Dalia Ficarro, Scott B. Udayakumar, Durga Gurbani, Deepak Tae, Hyun Seop Riddle, Steven M. Sim, Taebo Marto, Jarrod A. Jaenne, Pasi A. Crews, Craig M. Gray, Nathanael S. 2024-01-20T08:30:48Z 2024-01-20T08:30:48Z 2021-09-02 2014-12 1552-4450 https://pubs.kist.re.kr/handle/201004/126083 Her3 (also known as ErbB3) belongs to the epidermal growth factor receptor tyrosine kinases and is well credentialed as an anti-cancer target but is thought to be 'undruggable' using ATP-competitive small molecules because it lacks appreciable kinase activity. Here we report what is to our knowledge the first selective Her3 ligand, TX1-85-1, that forms a covalent bond with Cys721 located in the ATP-binding site of Her3. We demonstrate that covalent modification of Her3 inhibits Her3 signaling but not proliferation in some Her3-dependent cancer cell lines. Subsequent derivatization with a hydrophobic adamantane moiety demonstrates that the resultant bivalent ligand (TX2-121-1) enhances inhibition of Her3-dependent signaling. Treatment of cells with TX2-121-1 results in partial degradation of Her3 and serendipitously interferes with productive heterodimerization between Her3 with either Her2 or c-Met. These results suggest that small molecules will be capable of perturbing the biological function of Her3 and -60 other pseudokinases found in human cells. English NATURE PUBLISHING GROUP HER2-POSITIVE BREAST-CANCER TYROSINE KINASE LUNG-CANCER EXTENDED 5-SUBSTITUENT ADJUVANT CHEMOTHERAPY SELECTIVE INHIBITORS MET AMPLIFICATION OVARIAN-CANCER PROTEIN DOMAIN Pharmacological targeting of the pseudokinase Her3 Article 10.1038/nchembio.1658 1 NATURE CHEMICAL BIOLOGY, v.10, no.12, pp.1006 - + NATURE CHEMICAL BIOLOGY 10 12 1006 + scie scopus 000345122300007 Biochemistry & Molecular Biology Biochemistry & Molecular Biology Article HER2-POSITIVE BREAST-CANCER TYROSINE KINASE LUNG-CANCER EXTENDED 5-SUBSTITUENT ADJUVANT CHEMOTHERAPY SELECTIVE INHIBITORS MET AMPLIFICATION OVARIAN-CANCER PROTEIN DOMAIN